Ehlerding EB - Search Results

1

CD38-Targeted Theranostics of Lymphoma with ⁸⁹Zr/¹⁷⁷Lu-Labeled Daratumumab.

Kang L, Li C, Rosenkrans ZT, Huo N, Chen Z, Ehlerding EB, Huo Y, Ferreira CA, Barnhart TE, Engle JW, Wang R, Jiang D, Xu X, Cai W. Kang L, et al. Among authors: ehlerding eb. Adv Sci (Weinh). 2021 Mar 15;8(10):2001879. doi: 10.1002/advs.202001879. eCollection 2021 May. Adv Sci (Weinh). 2021. PMID: 34026426 Free PMC article.

2

CD38 as a PET Imaging Target in Lung Cancer.

Ehlerding EB, England CG, Jiang D, Graves SA, Kang L, Lacognata S, Barnhart TE, Cai W. Ehlerding EB, et al. Mol Pharm. 2017 Jul 3;14(7):2400-2406. doi: 10.1021/acs.molpharmaceut.7b00298. Epub 2017 Jun 8. Mol Pharm. 2017. PMID: 28573863 Free PMC article.

3

⁸⁹Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer.

England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, Barnhart TE, McNeel DG, Huang P, Cai W. England CG, et al. Among authors: ehlerding eb. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):110-120. doi: 10.1007/s00259-017-3803-4. Epub 2017 Aug 19. Eur J Nucl Med Mol Imaging. 2018. PMID: 28821924 Free PMC article.

4

Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.

Kang L, Jiang D, Ehlerding EB, Barnhart TE, Ni D, Engle JW, Wang R, Huang P, Xu X, Cai W. Kang L, et al. Among authors: ehlerding eb. Mol Pharm. 2018 Apr 2;15(4):1627-1634. doi: 10.1021/acs.molpharmaceut.7b01168. Epub 2018 Mar 20. Mol Pharm. 2018. PMID: 29537283 Free PMC article.

5

Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with ⁸⁹Zr-Df-Atezolizumab.

Ehlerding EB, Lee HJ, Barnhart TE, Jiang D, Kang L, McNeel DG, Engle JW, Cai W. Ehlerding EB, et al. Bioconjug Chem. 2019 May 15;30(5):1434-1441. doi: 10.1021/acs.bioconjchem.9b00178. Epub 2019 Apr 19. Bioconjug Chem. 2019. PMID: 30973703 Free PMC article.

6

CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma.

Wei W, Jiang D, Ehlerding EB, Barnhart TE, Yang Y, Engle JW, Luo QY, Huang P, Cai W. Wei W, et al. Among authors: ehlerding eb. Adv Sci (Weinh). 2019 Feb 27;6(9):1801237. doi: 10.1002/advs.201801237. eCollection 2019 May 3. Adv Sci (Weinh). 2019. PMID: 31065511 Free PMC article.

7

^86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics.

Ferreira CA, Ehlerding EB, Rosenkrans ZT, Jiang D, Sun T, Aluicio-Sarduy E, Engle JW, Ni D, Cai W. Ferreira CA, et al. Among authors: ehlerding eb. Mol Pharm. 2020 May 4;17(5):1697-1705. doi: 10.1021/acs.molpharmaceut.0c00127. Epub 2020 Mar 31. Mol Pharm. 2020. PMID: 32202792 Free PMC article.

8

Smaller Agents for Larger Therapeutic Indices: Nanoscale Brachytherapy with 177Lu-Labeled Gold Nanoparticles.

Ehlerding EB, Cai W. Ehlerding EB, et al. J Nucl Med. 2016 Jun;57(6):834-5. doi: 10.2967/jnumed.116.173278. Epub 2016 Feb 11. J Nucl Med. 2016. PMID: 26912431 Free PMC article. No abstract available.

9

Biodegradable and Renal Clearable Inorganic Nanoparticles.

Ehlerding EB, Chen F, Cai W. Ehlerding EB, et al. Adv Sci (Weinh). 2016 Feb;3(2):1500223. doi: 10.1002/advs.201500223. Epub 2015 Oct 27. Adv Sci (Weinh). 2016. PMID: 27429897 Free PMC article.

10

Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.

England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W. England CG, et al. Among authors: ehlerding eb. J Nucl Med. 2017 Jan;58(1):162-168. doi: 10.2967/jnumed.116.177857. Epub 2016 Aug 4. J Nucl Med. 2017. PMID: 27493273 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page